Release from 6-10-96
NEWTON, Mass., June 10 /PRNewswire/ -- Matritech, Inc. (Nasdaq: NMPS; BSE:
MPS) announced today that J. Robert Buchanan, M.D., former General Director
of Boston's Massachusetts General Hospital (MGH), has joined the Company's
board of directors.
"Dr. Buchanan is an experienced physician and senior healthcare executive,
and Matritech is extremely pleased that he has chosen to help us establish
Nuclear Matrix Proteins (NMPs) as a reliable cancer- detection system
applicable to the major cancer types," said Stephen D. Chubb, Matritech's
chief executive officer. "We believe that the addition of Dr. Buchanan to
Matritech's board of directors further underscores the promise of NMP science
and its potential clinical utility."
Dr. Buchanan, 68, joined MGH in 1982 and retired last year from his position
as General Director of the hospital and served as a professor of medicine at
Harvard University Medical School. From 1977-1982 Dr. Buchanan served as
President of Chicago's Michael Reese Hospital and Medical Center as well as
on the faculty of the University of Chicago's Pritzker School of Medicine.
Other directors, in addition to Matritech's chairman/CEO Stephen D. Chubb and
president/COO David L. Corbet, include: Thomas R. Morse, managing director,
Philadelphia Ventures, Inc.; David Rubinfien; T. Stephen Thompson, president
and chief executive officer, IMMTECH International, Inc.; and C. William
Zadel, president and chief executive officer of Millipore Corporation.
Matritech, Inc., based in Newton, MA, is using its proprietary Nuclear Matrix
Protein (NMP) technology, discovered at the Massachusetts Institute of
Technology (MIT) and Johns Hopkins University School of Medicine and licensed
exclusively to Matritech, to develop and commercialize innovative serum-,
cell- and urine-based NMP diagnostics that enable physicians to reliably
detect and monitor the presence of cancer.
CO: Matritech, Inc.
ST: Massachusetts
IN: MTC
SU: PER
06/10/96 12:29 EDT prnewswire.com |
